Status: Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Participants needed: 120
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: 858 Therapeutics, Inc.Updated: Mar 27, 2026Locations: 14
Eligibility criteria
Males and females of age ≥ 18 years at the time of signing the informed consent... [+7]
Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day... [+11]